New drug aimed at saving lives after stem cell transplants

NCT ID NCT07347990

Not yet recruiting Disease control Sponsor: First Affiliated Hospital of Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a drug called iptacopan in 30 people who have a serious blood vessel problem after a stem cell transplant. The drug aims to block a part of the immune system that damages blood vessels. Researchers will check if it helps patients live longer and recover organ function over 6 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: iptacopan
What this could lead to: If it works, this could offer a new treatment option for a serious complication after stem cell transplants, potentially improving survival and organ function.
What could go wrong: This is a small, early-phase study with only 30 participants and no comparison group. The drug may not work as hoped, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

thrombotic microangiopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) THROMBOTIC MICROANGIOPATHY

Contacts and locations

Locations

The First Affiliated Hospital of Zhejiang University School of Medicine

Hangzhou, China, 310003, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.